rate in the NOM group was 21.3% at a mean of 15.6 (7.0) months. Surgical salvage was possible and was undertaken in 93.2% of these patients. Overall survival in the NOM group was 91.7%, while disease-free survival was 82.7%. For the comparison proctectomy group, pooled rates of local recurrence, overall survival, and disease-free survival were 8.4, 92.4, and 87.5%, respectively. Conclusion. NOM may be a feasible option for surgically eligible rectal cancer patients with cCR after nCRT. Before such a strategy can be widely implemented, further prospective data are required with standardized definitions, diagnostic criteria, and management protocols, with an emphasis on shared patient-provider decision making and patient-centered outcomes.
The standard of care in stage II and III rectal cancer treatment is total mesorectal excision with neoadjuvant radiation or chemoradiation followed by adjuvant chemotherapy. Among those patients who undergo neoadjuvant treatment, approximately 10-20% will achieve a pathologic complete response which has been associated with excellent long-term prognosis for both local and distant control. 1, 2 However, surgery for rectal cancer is associated with significant morbidity and a potential adverse impact on quality of life. Because of this, there has been increasing interest in the pursuit of strategies that incorporate nonoperative management (NOM) after chemoradiation therapy. 3 The major difficulty with this approach has been the challenge of identifying patients with pathological complete response (pCR) using clinical assessment, which is presently limited and inaccurate. 4 Complete clinical response (cCR) has been reportedly observed in upwards of 40% of patients, of whom more than half will have residual viable tumor identified on pathologic review of the surgical specimen. As a result, selection of patients for NOM based on the surrogate measure of cCR remains a balance of risk proposition, the safety of which is being actively investigated. 5, 6 Even in the context of published clinical trials, there is no standardization of patient selection criteria, diagnostic methods, or management algorithms. 7, 8 This makes interpretation of the data in a clinically meaningful way very difficult for healthcare providers and patients. 9 Thus, the decision to consider a nonoperative treatment strategy requires the consideration of a complex set of trade-offs regarding potential treatment outcomes in the setting of significant uncertainty. 10, 11 The aim of this clinical review was to summarize the available data on NOM as an alternative to total mesorectal excision, with the specific intention of formulating standardized selection and diagnostic criteria, as well as management and surveillance protocols on which to base future investigation.
METHODS

Research Question
In patients with rectal cancer who have a cCR after neoadjuvant chemoradiation (nCRT) and who undergo NOM, what is the rate of pelvic disease failure (recurrence or regrowth)? What is the rate of curative salvage surgery after treatment failure? Among salvaged patients, what proportion require a colostomy?
Search Strategy
Relevant primary studies published between January 2004 and November 2016 were identified from the Ovid MEDLINE, Cochrane, and Ovid EMBASE electronic databases (including in-process and non-indexed citations). A highly sensitive search strategy was employed (electronic supplementary material 1) incorporating the following elements, with no language restriction:
• Population: Patients with rectal cancer at least 18 years of age treated with nCRT eligible for curative surgical resection.
• Intervention: NOM after nCRT with assessment of cCR, but without local excision.
• Comparator: Rectal cancer patients treated with standard of care: nCRT followed by surgical resection (proctectomy).
• Outcomes:
• Primary: Rate of local regrowth (including mesorectal nodal disease).
• Secondary: Overall and disease-free survival, curative salvage surgery rate, sphincter preservation/ colostomy rate.
The references of the chosen articles were also screened for inclusion. For multiple publications reporting on the same patient population, the most recent publication was used.
Inclusion criteria were:
• Clinical controlled (RCTs, cohort) or observational studies (prospective and retrospective); • Studies including adult human subjects aged C18 years eligible for curative resection; • Included patients with primary rectal adenocarcinoma who underwent nCRT; • Provided sufficient description of treatment modalities;
• Provided criteria for diagnosing a cCR.
Exclusion criteria included:
• Systematic reviews, meta-analyses, nonhuman studies, editorials; • Studies in which patients were only treated with neoadjuvant radiotherapy; • Studies that only reported data for local excision of the primary tumor (in either study arm); • Studies in which only comorbid, frail, and/or palliative patients were treated with NOM; • Studies that did not report any clinical outcome data;
• Studies that did not have follow-up data.
Appraisal and Data Extraction
All results identified from the search were entered into a unified database, after which duplicate results were removed. Two authors (TS, BP) independently reviewed the titles and abstracts of every record identified by the search and decided on inclusions based on the above criteria. Differences in assessment were resolved by consensus and evaluation by a third reviewer (GJC). One author performed data extraction (BP).
Quality Assessment
Two reviewers independently assessed the risk of bias based on the Newcastle-Ottawa Scale for nonrandomized studies. Differences in assessment were resolved by consensus and evaluation by a third reviewer (GJC).
Data Synthesis
A narrative synthesis of the findings from the included studies was developed and structured around diagnostic criteria, patient selection, type of intervention, and outcome. Summary data were presented as mean (standard deviation) for continuous variables, and percentages for categorical variables. We anticipated that data summation by meta-analysis would be of limited scope because of study heterogeneity; however, we planned to attempt to pool results, if this was possible, where studies have used the same intervention, comparator, and outcome measure.
RESULTS
Search Results
In total, 5566 citations were identified from the initial search. After screening of the titles, 411 abstracts were identified for further review (Fig. 1 ). There was a dramatic increase in the total number of publications between 2006 and 2016 (Fig. 2) . 12 Ultimately, 15 studies met the inclusion criteria (all of which were published between 2009 and 2016) and were selected for the final assessment. Among a total of 920 patients included in the studies, 575 (62.5%) underwent NOM after a cCR. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Eight studies reported data for an adequate control proctectomy group, but there was significant variation. Four studies used a post-surgical pCR group for comparison, 14, 16, 25, 26 two used cCR tumors undergoing surgery, 19, 20 one used both, 22 and one used a surgical group matched for clinical stage (regardless of tumor response). 23 Outcome data for incomplete response, nonresponse, and local excision were excluded from comparisons as these were not regarded as adequate control group data. 13, 15, 17, 18, 21, 27 Due to this significant heterogeneity in the control arms (and follow-up duration), formal meta-analysis of the results was not performed. 
Study Quality Assessment
Quality assessment is presented in Table 1 . Overall, studies generally described the selection of the NOM group and their outcomes with remarkable detail (Table 4 , 5 in Appendix); however, the description of the control group was deficient in many of the studies, which led to fewer stars awarded to those studies. For comparability, only four studies (27%) included a comparable group of cCR patients opting for, or randomized to, surgery. Another four studies compared NOM patients with pCR patients; however, the remaining studies (7; 47%) did not list any comparison group. Oncologic outcomes were reported for all NOM groups.
Neoadjuvant and Adjuvant Treatment
The neoadjuvant treatment regimen was outlined in all included studies (see Table 1 ). Long-course radiotherapy (45-65 Gy) was administered in all studies, with 50.4 Gy being the most common treatment dose. In all instances, concurrent chemotherapy was fluoropyrimidine-based. In contrast, the use of consolidation or adjuvant chemotherapy was highly variable, ranging from frequent use 18, 25, 26 to use only if staged as node positive prior to neoadjuvant treatment, 15, 21 infrequent use, 14, 20, 23 and complete omission. 13, 16, 17, 19, 22 Consolidation or adjuvant chemotherapy, when used, was most commonly 5-fluorouracil-based, with the addition of oxaliplatin in two studies. 21, 25 Patient Selection Criteria for Nonoperative Management (NOM)
Tumor distance from the anal verge was defined in 12 studies and varied, although most only included tumors in the mid and low rectum (Table 4 in Appendix). Clinical staging inclusion criteria were reported in 13 studies, most commonly cT2-T4, N0-2, M0, with exclusion of early T stage (T0/T1) and stage IV patients. Three studies excluded T4 patients, 13, 20, 26 and only one study included patients with metastatic stage IV disease. 26 
Complete Clinical Response Diagnosis
The clinical diagnosis of complete response required correlation of digital rectal examination (DRE), endoscopy, and magnetic resonance imaging (MRI) in most studies (Table 5 in Appendix). Uniformly, tumor had to be absent on DRE, but definitions of endoscopic and imaging findings varied. Common endoscopic criteria included 'flat scar' and 'absence of ulceration', while MRI criteria were 'significant regression with fibrosis and with no residual tumor', 'low signal intensity on T2 images', and 'no evidence of extrarectal residual disease'. Negative biopsies of the residual lesion were only explicitly mandated in two studies. 16, 21 Surveillance Protocol Clinical examination, proctoscopy, carcinoembryonic antigen (CEA) level, MRI of the rectum, and computed tomography (CT) of the chest, abdomen, and pelvis were used consistently for surveillance (Table 6 in Appendix). Although the timing of these investigations was highly variable, clinical assessment/proctoscopy was most commonly recommended every 1-3 months for at least 1 year, with reducing frequency thereafter. CEA level was commonly performed every 3-6 months long term, while CT and MRI imaging were both most commonly performed every 6 months for the first year and then yearly thereafter. Positron emission tomography (PET)-CT was utilized in only five studies. 13, 16, 20, 26, 27 Outcomes Follow-up duration was reported in all studies for NOM and comparison surgery groups (three studies reported overall follow-up duration for both groups together and this duration was assumed to be the same in each group). The weighted mean follow-up time was thus 39.4 (12.7) months in the NOM group and 39.8 (5.1) months in the surgery group ( Table 2 ). The pooled regrowth rate (including mesorectal nodal disease) was 21.3% at a weighted mean of 15.6 (7.0) months. Surgical salvage was possible and was undertaken in 93.2% of patients who developed a regrowth (with the rest most commonly reported as insalvagable/palliated). For patients undergoing salvage, the colostomy rate was 54.4% (the overall colostomy rate for the NOM group was 12.0% as intention to treat vs. 36.1% in the surgery group). Overall survival in the NOM group (reported in 14 studies) was 91.7%, and disease-free survival (reported in all studies) was 82.7%. For the comparison proctectomy group, pooled rates of local recurrence, overall survival, and disease-free survival were 8.4, 92.4, and 87.5%, respectively.
DISCUSSION
We performed a systematic review of published data on the NOM of rectal cancer after cCR to CRT. While there was significant heterogeneity between studies, particularly with respect to comparison groups, which prevented formal metaanalysis. In addition, there was variation in the inclusion criteria, treatment strategy, and follow-up duration. Furthermore, small sample sizes, short duration of follow-up, reporting bias from retrospective studies, and differences in entry criteria have likely influenced our point estimates. Despite this, some insights were gained into the efficacy and potential advantages of this procedure in selected patients. After a weighted mean follow-up of over 3 years, the pooled regrowth rate was 21.3%, with surgical salvage possible in a majority, but not all, patients ([90%), and an overall survival of[90% in the whole group. The colostomy rate was much lower than in the surgical resection group.
In the absence of level 1 evidence for the oncologic efficacy for NOM strategies, surgical resection remains the standard of care. However, based on the available data, it would be reasonable to offer NOM as a prospectively evaluated option for active surveillance to selected patients with cCR. In doing this, it is important to explain the potential benefits and harms of this management approach in detail, and ensure that the patient is able to make an informed decision. While it may be difficult to conduct randomized controlled trials on this topic, it is imperative that this approach is investigated through high-quality prospective and comparative data collection, with standardized definitions to enable interstudy and interinstitutional comparisons. 28 Based on the reported data, we propose the following guidelines for prospective management, erring on the side of being conservative where possible due to the still experimental nature of the intervention and the difficulty in accurately identifying a pCR based on clinical characteristics, 29, 30 and with an emphasis on patient-centered decision making and outcomes (Table 3) .
Neoadjuvant and Adjuvant Treatment
Patients should undergo long-course combination chemoradiotherapy with fields that include the tumor, presacral nodes, mesorectal region, and internal iliac nodes. Generally, a three-or four-field technique should be used delivering 45 Gy in 25 fractions to the pelvis, and a 5.4 Gy boost (3 fractions) to the tumor bed and presacral region (total dose 50.4 Gy). Intensity-modulated radiation therapy (IMRT) may be considered in selected cases to 30 (72) 26 (61) 5 (12) 24. 2 4 (80) 3 (7) 46.7
62 (90) 57 (83) 1 (1.4)
(19)
Creavin et al. 80 (94) 78 (92) 12 (14) 14.6
11 (92) 6 (7) -----Nahas et al. • Histologically confirmed diagnosis of rectal adenocarcimona
• Radiologically measurable disease
• cT2-T4a, N?
• Nodal involvement confined to radiation field • Written informed consent for treatment and follow-up
• cT4b
• Tumor is causing symptomatic bowel obstruction (patients who have diverting ostomy are still eligible but obstructing tumor will preclude complete examination for response assessment)
• Any prior pelvic radiation
• Contraindication to fluoropyrimidine-based chemotherapy (e.g.
DPD deficiency)
• 
Patient Selection Criteria for NOM
All patients must undergo baseline DRE, endoscopy, complete radiographic staging evaluation, including CT of the chest/abdomen/pelvis, and a rectal cancer pelvic MRI (Table 4 in Appendix). An MRI of the abdomen, or PET/ CT, may be performed in lieu of the CT. The eligibility criteria, definition of a cCR, structured surveillance protocol, and prospective collection of relevant outcomes for NOM patients are summarized in Table 3 . Future guidelines will be informed by well-controlled prospective studies with clearly defined control groups of eligible patients who undergo surgery (and not NOM).
Limitations
A limitation to this analysis is the significant heterogeneity of the included studies. In addition, data on local excision were not included. While it has been proposed as a method of further improving patient selection by providing additional staging information, the role of local excision in the rectal cancer with cCR has yet to be clearly defined. There are also potential drawbacks, such as false negatives, false positives (particularly in terms of timing of the excision in the setting of a responding tumor), sphincter damage in very low tumors, the absence of nodal staging information, and the real risk of specimen fracture due to weakening of the rectal wall should proctectomy be required at a later date. The estimates for tumor regrowth in individual studies may be affected by the stringency of the inclusion criteria for the NOM strategy, and small sample size, which may be mitigated in part by evaluation of pooled data from all studies. Furthermore, NOM for comorbid and/or frail patients was not assessed in this review; however, published data suggest that NOM is superior to surgical resection in this patient population. 11 Finally, scientific meeting abstracts were not included in the search, and assessment of publication bias was not performed.
CONCLUSION
NOM with active surveillance may be a feasible option for surgically eligible rectal cancer patients with cCR after nCRT. However, before such a strategy can be widely implemented, further prospective data are required with standardized definitions, diagnostic criteria, and management protocols, with an emphasis on shared patientprovider decision making and patient-centered outcomes. [16] [17] [18] [20] [21] [22] [23] [24] [25] Not specified 3 14, 19, 27 N stage N1 7 13, 16, 17, 19, 20, 24, 25 N2 5 16, 17, 20, 24, 25 N? 5 15, [23] [24] [25] [26] Not specified 3 14, 19, 27 M stage M0 12 13, [15] [16] [17] [18] [20] [21] [22] [23] [24] [25] 27 M? 1 26 Not specified 2 14, 19 Bold items were most frequently used Superficial scar with minimal ulceration 2 13, 21 Absence of deep ulceration 1 22 Not defined 4 14, 16, 20, 26 Imaging Significant regression with fibrosis and without residual tumor 2 16, 20 Regression with no or minimal residual tumor or no extra-rectal disease 5 [17] [18] [19] 21, 22 Not (well) defined 8 [13] [14] [15] [23] [24] [25] [26] [27] Biopsy Negative biopsies 2 16, 21 Bold items were most frequently used DRE digital rectal examination Years 31 5 13, 16, 17, 19, 21 Bold items were most frequently used DRE digital rectal examination, CEA carcinoembryonic antigen, EUA examination under anesthesia, MRI magnetic resonance imaging, PET positron emission tomography, CT computed tomography
